Gimvekibart

Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research[1][2].

Product Specifications

CAS Number

[3037526-90-9]

UNSPSC

12352100

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

References & Citations

[1]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .|[2]Vasakova M, et al. IL-4 polymorphisms, HRCT score and lung tissue markers in idiopathic pulmonary fibrosis. Hum Immunol. 2013 Oct;74 (10) :1346-51.